MedTrace Logo

A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

NCT07222956 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-05-20

No results posted yet for this study

Summary

The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints. Approximately 20 participants with relapsing or progressive forms of MS will be recruited.

Conditions

  • Multiple Sclerosis (MS) - Relapsing-remitting
  • Multiple Sclerosis (MS) Secondary Progressive
  • Multiple Sclerosis (MS) Primary Progressive

Interventions

DRUG

Remibrutinib (Open Label)

100 mg remibrutinib, twice daily

Sponsors & Collaborators

Principal Investigators

  • Moein Amin, MD, MS · The Cleveland Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2030-10-30
Completion
2030-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07222956 on ClinicalTrials.gov